Analysis of the interaction of the human immunodeficiency virus type 1 gp120 envelope glycoprotein with the gp41 transmembrane glycoprotein

Journal of Virology

Volumn 71, Issue 12, 1997, Pages 9722-9731

  Wyatt, Richard ^a,b   Desjardin, Elizabeth ^a,b   Olshevsky, Udy ^a,b,e   Nixon, Chris ^a,b   Binley, James ^d   Olshevsky, Varda ^a,b   Sodroski, Joseph ^a,b,c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d ROCKEFELLER UNIVERSITY   (United States)

^e ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; EPITOPE; GLYCOPROTEIN; GLYCOPROTEIN GP 120; NEUTRALIZING ANTIBODY;

AMINO ACID SEQUENCE; ANTIBODY PRODUCTION; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; GENE DELETION; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOPRECIPITATION; PLASMID; PRIORITY JOURNAL; PROTEIN ANALYSIS; VIRUS TRANSFORMATION;

EID: 0030730243     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.71.12.9722-9731.1997     Document Type: Article

References (91)

1. Alkhatib, G., C. Combadiere, C. C. Broder, Y. Feng, P. M. Murphy, and E. Berger. 1996. CC-CKR5: a RANTES, MIP-1α, MIP-1β receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 272:1955-1958.
2. Allan, J., T. H. Lee, M. F. McLane, J. Sodroski, W. Haseltine, and M. Essex. 1983. Identification of the major envelope glycoprotein product of HTLV-III. Science 228:1091-1094.
3. Barre-Sinoussi, F., J. C. Chermann, F. Rey, M. T. Nugeyre, S. Chamaret, J. Gruest, C. Dauget, C. Axler-Bin, F. Vezinet-Brun, C. Rouzioux, W. Rozenbaum and L. Montagnier. 1983. Isolation of a T-lymphocyte retrovirus from a patient at risk for acquired immunodeficiency syndrome (AIDS). Science 220:868-871.
4. Berger, E., J. Sisler, and P. Earl. 1992. Human immunodeficiency virus type 1 envelope glycoprotein molecules containing membrane fusion-impairing mutations in the V3 region efficiently undergo soluble CD4-simulated gp120 release. J. Virol. 66:6208-6212.
5. Broder, C. C., P. Earl, D. Long, S. Abedon, B. Moss, and R. Doms. 1994. Antigenic implications of human immunodeficiency virus type 1 envelope quaternary structure: oligomer-specific and -sensitive monoclonal antibodies. Proc. Natl. Acad. Sci. USA 91:11699-11703.
6. Bugelski, P., H. Ellens, T. Hart, and R. Kirsh. 1991. Soluble CD4 and dextran sulfate mediate release of gp120 from HIV-1: implications for clinical trials. J. Acquired Immune Defic. Syndr. 4:923-924.
7. Cann, A. J., M. J. Churcher, M. Boyd, W. O'Brien, J.-Q. Zhao, J. Zack, and I. S. Y. Chen. 1992. The region of the envelope gene of human immunodeficiency virus type 1 responsible for determination of cell tropism. J. Virol. 66:305-309.
8. Cao, J., L. Bergeron, E. Helseth, M. Thali, H. Repke, and J. Sodroski. 1993. Effects of amino acid changes in the extracellular domain of the human immunodeficiency virus type 1 gp41 envelope glycoprotein. J. Virol. 67:2747-2755.
9. Capon, D., S. Chamow, J. Mordenti, S. Marsters, T. Gregory, H. Mitsuya, R. Byrn, C. Lucas, F. Wurm, J. Groopman, and D. Smith. 1989. Designing CD4 immunoadhesins for AIDS therapy. Nature 337:525-531.
10. Cheng-Mayer, C., M. Quiroga, J. W. Tung, D. Dina, and J. A. Levy. 1990. Viral determinants of human immunodeficiency virus type 1 T-cell or macrophage tropism, cytopathogenicity, and CD4 antigen modulation. J. Virol. 64:4390-4398.
11. Chesebro, B., J. Nishio, S. Perryman, A. Cann, W. O'Brien, I. S. Y. Chen, and K. Wehrly. 1991. Identification of human immunodeficiency virus envelope gene sequences influencing viral entry into CD4-positive HeLa cells, T-leukemia cells, and macrophages. J. Virol. 65:5782-5789.
12. Chesebro, B., K. Wehrly, J. Nishio, and S. Perryman. 1992. Macrophage-tropic human immunodeficiency virus isolates from different patients exhibit unusual V3 envelope sequence homogeneity in comparison with T-cell-tropic isolates: definition of critical amino acids involved in cell tropism. J. Virol. 66:6547-6554.
13. Choe, H., M. Farzan, Y. Sun, N. Sullivan, B. Rollins, P. D. Ponath, L. Wu, C. R. MacKay, G. LaRosa, W. Newman, N. Gerard, C. Gerard, and J. Sodroski. 1996. The β-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 85:1-20.
14. Dalgleish, A. G., P. C. L. Beverley, P. R. Clapham, D. H. Crawford, M. F. Greaves, and R. A. Weiss. 1984. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 312:763-767.
15. Deen, K., J. S. McDougal, R. Inacker, G. Folena-Wassterman, J. Arthos, J. Rosenberg, P. Maddon, R. Axel, and R. Sweet. 1988. A soluble form of CD4 (T4) protein inhibits AIDS virus infection. Nature 331:82-84.
16. Deng, H. K., S. Choe, W. Ellmeier, R. Liu, D. Unutmaz, M. Burkhart, P. di Marzio, S. Marmon, R. E. Sutton, C. M. Hill, C. Davis, S. C. Peiper, T. J. Schall, D. R. Littman, and N. R. Landau. 1996. Identification of a major co-receptor for primary isolates of HIV-1. Nature 381:661-666.
17. Doranz, B., J. Rucker, Y. Yi, R. Smyth, M. Samson, S. Peiper, M. Parmentier, R. Collman, and R. Doms. 1996. A dual-tropic primary HIV-1 isolate that uses fusin and the β-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 85:1149-1158.
18. + cells is mediated by the chemokine receptor CC-CKR-5. Nature 381:667-673.
19. Earl, P. L., R. W. Doms, and B. Moss. 1990. Oligomeric structure of the human immunodeficiency virus type 1 envelope glycoprotein. Proc. Natl. Acad. Sci. USA 87:648-652.
20. Earl, P. L., B. Moss, and R. W. Doms. 1991. Folding, interaction with GRP78-BiP, assembly and transport of the human immunodeficiency virus type 1 envelope protein. J. Virol. 65:2047-2055.
21. Fauci, A., A. Macher, D. Longo, H. C. Lane, A. Rook, H. Masur, and E. Gelman. 1984. Acquired immunodeficiency syndrome: epidemiologic, clinical and therapeutic considerations. Ann. Intern. Med. 100:92-106.
22. Feng, Y., C. C. Broder, P. E. Kennedy, and E. A. Berger. 1996. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 272:872-877.
23. Fisher, R., E. Collati, L. Ratner, R. Gallo, and F. Wong-Staal. 1985. A molecular clone of HTLV-III with biological activity. Nature 316:262-265.
24. Fisher, R., J. Bertonis, W. Meier, V. Johnson, D. Costopoulos, T. Liu, R. Tizard, B. Walker, M. Hirsch, R. Schooley, and R. Flavell. 1988. HIV infection is blocked in vitro by recombinant soluble CD4. Nature 331:76-78.
25. Fouts, T. R., J. M. Binley, A. Trkola, J. E. Robinson, and J. P. Moore. 1997. Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex. J. Virol. 71:2779-2785.
26. Freed, E., D. Myers, and R. Risser. 1990. Characterization of the fusion domain of the human immunodeficiency virus type 1 envelope glycoprotein gp41. Proc. Natl. Acad. Sci. USA 87:4650-4654.
27. Freed, E., D. Myers, and R. Risser. 1991. Identification of the principal neutralizing determinant of human immunodeficiency virus type 1 as a fusion domain. J. Virol. 65:190-194.
28. Fu, Y.-K., T. Hart, Z. Jonak, and P. Bugelski. 1993. Physicochemical dissociation of CD4-mediated syncytium formation and shedding of HIV-1 gp120. J. Virol. 67:3818-3825.
29. Fung, M. S. C., C. R. Y. Sun, W. L. Gordon, R.-S. Liou, T. W. Chang, W. N. C. Sun, E. S. Daar, and D. D. Ho. 1992. Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120. J. Virol. 66:848-856.
30. Gallo, R. C., S. Z. Salahuddin, M. Popovic, G. M. Shearer, M. Kaplan, B. F. Haynes, T. J. Palker, R. Redfield, J. Oleske, B. Safai, G. White, P. Foster, and P. D. Markham. 1984. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science 224:500-503.
31. Hart, T., R. Kirsch, H. Ellens, R. Sweet, D. Lambert, S. Petteway, J. Leary, and P. Bugelski. 1991. Binding of soluble CD4 proteins to HIV-1 and infected cells induces release of envelope glycoprotein gp120. Proc. Natl. Acad. Sci. USA 88:2189-2193.
32. Helseth, E., M. Kowalski, D. Gabuzda, U. Olshevsky, W. Haseltine, and J. Sodroski. 1990. Rapid complementation assays measuring replicative potential of human immunodeficiency virus type 1 envelope glycoprotein mutants. J. Virol. 64:2416-2420.
33. Helseth, E., U. Olshevsky, C. Furman, and J. Sodroski. 1991. Human immunodeficiency virus type 1 gp120 envelope glycoprotein regions important for association with the gp41 transmembrane glycoprotein. J. Virol. 65:2119-2123.
34. Ho, D., J. McKeating, X. Li, T. Moudgil, E. Daar, N.-C. Sun, and J. Robinson. 1991. Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody. J. Virol. 65:489-493.
35. Hussey, R., N. Richardson, M. Kowalski, N. Brown, H. Change, R. Siliciano, T. Dorfman, B. Walker, J. Sodroski, and E. Reinherz. 1988. A soluble CD4 protein selectively inhibits HIV replication and syncytium formation. Nature 331:78-81.
36. Hwang, S. S., T. J. Boyle, H. K. Lyerly, and B. R. Cullen. 1991. Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. Science 253:71-74.
37. Ivanoff, L., D. Looney, C. McDanal, J. Morris, F. Wong-Staal, A. Langlois, S. Petteway, and T. Matthews. 1991. Alteration of HIV-1 infectivity and neutralization by a single amino acid replacement in the V3 loop domain. AIDS Res. Hum. Retroviruses 7:595-603.
38. Javaherian, K., A. J. Langlois, C. McDanal, K. L. Ross, L. I. Eckler, C. L. Jellis, A. T. Profy, J. R. Rusche, D. P. Bolognesi, S. D. Putney, and T. J. Matthews. 1989. Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. Proc. Natl. Acad. Sci. USA 86:6768-6772.
39. Jeffs, S., J. McKeating, S. Lewis, H. Craft, D. Biram, P. Stephens, and R. Brady. 1996. Antigenicity of truncated forms of the human immunodeficiency virus type 1 envelope glycoprotein. J. Gen. Virol. 77:1403-1410.
40. Kang, C.-Y., P. Nara, S. Chamat, V. Caralli, T. Ryskamp, N. Haigwood, R. Newman, and H. Kohler. 1991. Evidence for non-V3-specific neutralizing antibodies that interfere with gp120/CD4 binding in human immunodeficiency virus-infected humans. Proc. Natl. Acad. Sci. USA 88:6171-6175.
41. Kang, C.-Y., K. Hariharan, M. R. Posner, and P. Nara. 1993. Identification of a new neutralizing epitope conformationally affected by the attachment of CD4 to gp120. J. Immunol. 151:449-457.
42. Klatzmann, D., E. Champagne, S. Chamaret, J. Gruest, D. Guetard, T. Hercend, J. C. Gluckman, and L. Montagnier. 1984. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature 312:767-768.
43. Kowalski, M., J. Potz, L. Basiripour, T. Dorfman, W. G. Goh, E. Terwilliger, A. Dayton, C. Rosen, W. Haseltine, and J. Sodroski. 1987. Functional regions of the human immunodeficiency virus envelope glycoprotein. Science 237: 1351-1355.
44. Lapham, C., J. Ouyang, B. Chandrasekhar, N. Nguyen, D. Dimitrov, and H. Golding. 1996. Evidence for cell-surface association between fusin and the CD4-gp120 complex in human cell lines. Science 274:602-605.
45. Leonard, C., M. Spellman, L. Riddle, R. Harris, J. Thomas, and T. Gregory. 1990. Assignment of intrachain disulfide bonds and characterization of potential glycoslation sites of the type 1 human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J. Biol. Chem. 265:10373-10382.
46. Lu, M., S. Blackow, and P. Kim. 1995. A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat. Struct. Biol. 2:1075-1082.
47. Maddon, P., A. Dalgleish, J. S. McDougal, P. Clapham, R. Weiss, and R. Axel. 1986. The T4 gene encodes the AIDS receptor and is expressed in the immune system and the brain. Cell 47:333-348.
48. + T Cells by a complex of the 100 K viral protein and the T4 molecule. Science 231:382-385.
49. McKeating, J., C. Shotton, J. Cordell, S. Graham, P. Balfe, N. Sullivan, M. Charles, M. Page, A. Bolmstedt, S. Olofsson, S. Kayman, Z. Wu, A. Pinter, C. Dean, J. Sodroski, and R. Weiss. 1993. Characterization of neutralizing monoclonal antibodies to linear and conformation-dependent epitopes within the first and second variable domains of human immunodeficiency virus type 1 gp120. J. Virol. 67:4932-4944.
50. Moore, J., J. McKeating, R. Weiss, and Q. Sattentau. 1990. Dissociation of gp120 from HIV-1 virions induced by soluble CD4. Science 250:1139-1142.
51. Moore, J., J. McKeating, Y. Huang, A. Ashkenazi, and D. Ho. 1992. Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates. J. Virol. 66:235-243.
52. Moore, J., Q. Sattentau, H. Yoshiyama, M. Thali, M. Charles, N. Sullivan, S.-W. Poon, M. Fung, F. Traincard, J. Robinson, D. D. Ho, and J. Sodroski. 1993. Probing the structure of the V2 domain of the human immunodeficiency virus type 1 surface glycoprotein gp120 with a panel of eight monoclonal antibodies: the human immune response to the V1 and V2 domains. J. Virol. 67:6136-6151.
53. Moore, J., Q. Sattentau, R. Wyatt, and J. Sodroski. 1994. Probing the structure of the human immunodeficiency virus surface glycoprotein gp120 with a panel of monoclonal antibodies. J. Virol. 68:469-484.
54. Moore, J. P., R. L. Willey, G. K. Lewis, J. Robinson, and J. Sodroski. 1994. Immunological evidence for interactions between the first, second, and fifth conserved domains of the gp120 surface glycoprotein of human immunodeficiency virus type 1. J. Virol. 68:6836-6847.
55. Moore, J. P., and D. D. Ho. 1993. Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans. J. Virol. 67:863-875.
56. Moore, J. P., Y. Cao, L. Qing, Q. J. Sattentau, J. Pyati, R. Koduri, J. Robinson, C. F. Barbas III, D. R. Burton, and D. D. Ho. 1995. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120 and their neutralization is not predicted by studies with monomeric gp120. J. Virol. 69:101-109.
57. Moore, J. P., and J. Sodroski. 1996. Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein. J. Virol. 70:1863-1872.
58. Myers, G., J. Berzofsky, B. Korber, R. Smith, and G. Pavlakis. 1992. Human retroviruses and AIDS. A compilation and analysis of nucleic acid and amino acid sequences. Los Alamos National Laboratory, Los Alamos, N.Mex.
59. Page, K., S. Stearns, and D. Littman. 1992. Analysis of mutations in the V3 domain of gp160 that affect fusion and infectivity. J. Virol. 66:524-533.
60. Pinter, A., W. J. Honnen, S. A. Tilley, C. Bona, H. Zaghouani, M. K. Gorny, and S. Zolla-Pazner. 1989. Oligomeric structure of gp41, the transmembrane protein of human immunodeficiency virus type 1. J. Virol. 63:2674-2679.
61. Pollard, S., M. D. Rosa, J. Rosa, and D. Wiley. 1992. Truncated variants of gp120 bind CD4 with high affinity and suggest a minimum CD4 binding region. EMBO J. 11:585-591.
62. Posner, M., T. Hideshima, T. Cannon, M. Mukherjee, K. Mayer, and R. Byrn. 1991. An IgG human monoclonal antibody which reacts with HIV-1 gp120, inhibits virus binding to cells, and neutralizes infection. J. Immunol. 146:4325-4332.
63. Putney, S., T. Matthews, W. G. Robey, D. Lynn, M. Robert-Guroff, W. Mueller, A. Langlois, J. Ghrayeb, S. Petteway, K. Weinhold, P. Fischinger, F. Wong-Staal, R. Gallo, and D. Bolognesi. 1986. HTLV-III/LAV-neutralizing antibodies to an E. Coli-produced fragment of the virus envelope. Science 234:1392-1395.
64. Robey, W. G., B. Safai, S. Oroszlan, L. Arthur, M. Gonda, R. Gallo, and P. J. Fischinger. 1985. Characterization of envelope and core structural gene products of HTLV-III with sera from AIDS patients. Science 228:593-595.
65. Robinson, J. Unpublished observations.
66. Rusche, J. R., K. Javaherian, C. McDanal, J. Petro, D. L. Lynn, R. Grimaila, A. Langlois, R. C. Gallo, L. O. Arthur, P. J. Fischinger, D. P. Bolognesi, S. D. Putney, and T. J. Matthews. 1988. Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino-acid sequence of the viral envelope gp120. Proc. Natl. Acad. Sci. USA 85:3198-3202.
67. Sattentau, Q., and J. Moore. 1991. Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding. J. Exp. Med. 174:407-415.
68. Sattentau, Q., J. Moore, F. Vignaux, F. Traincard, and P. Poignard. 1993. Conformational changes induced in the envelope glycoproteins of human and simian immunodeficiency viruses by soluble receptor binding. J. Virol. 67:7383-7393.
69. Sattentau, Q. J., and J. P. Moore. 1995. Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer. J. Exp. Med. 182:185-196.
70. Schawaller, M., G. E. Smith, J. Skehel, and D. Wiley. 1989. Studies with cross-linking reagents on the oligomeric structure of the env glycoprotein of HIV. Virology 172:367-369.
71. Shioda, T., J. A. Levy, and C. Cheng-Mayer. 1991. Macrophage and T cell-line tropisms of HIV-1 are determined by specific regions of the envelope gp120 gene. Nature 349:167-169.
72. Shotton, C., C. Arnold, Q. Sattentau, J. Sodroski, and J. McKeating. 1995. Identification and characterization of monoclonal antibodies specific for polymorphic antigenic determinants within the V2 region of the human immunodeficiency virus type 1 envelope glycoprotein. J. Virol. 69:222-230.
73. Smith, D., R. Byrn, S. Marsters, T. Gregory, J. Groopman, and D. Capon. 1987. Blocking of HIV-1 infectivity by a soluble secreted form of the CD4 antigen. Science 238:1704-1707.
74. Starcich, B. R., B. H. Hahn, G. M. Shaw, P. D. McNeely, S. Modrow, H. Wolf, W. P. Parks, S. F. Josephs, R. C. Gallo, and F. Wong-Staal. 1986. Identification and characterization of conserved and variable regions of the envelope gene of HTLV-III/LAV, the retrovirus of AIDS. Cell 45:637-648.
75. Steimer, K. S., C. J. Scandella, P. V. Skiles, and N. L. Haigwood. 1991. Neutralization of divergent HIV-1 isolates by conformation-dependent human antibodies to gp120. Science 254:105-108.
76. Stein, B. S., S. D. Gouda, J. D. Lifson, R. C. Penhallow, K. G. Bensch, and E. G. Engelman. 1987. pH-independent HIV entry into CD4-positive T cells via virus envelope fusion to the plasma membrane. Cell 49:659-668.
77. Sullivan, N., M. Thali, C. Furman, D. Ho, and J. Sodroski. 1993. Effect of amino acid changes in the V2 region of the human immunodeficiency virus type 1 gp120 glycoprotein on subunit association, syncytium formation, and recognition by a neutralizing antibody. J. Virol. 67:3674-3679.
78. Sullivan, N., Y. Sun, J. Li, W. Hoffmann, and J. Sodroski. 1995. Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T cell line-passaged human immunodeficiency virus type 1 isolates. J. Virol. 69:4413-4422.
79. Thali, M., U. Olshevsky, C. Furman, D. Gabuzda, M. Posner, and J. Sodroski. 1991. Characterization of a discontinuous human immunodeficiency virus type 1 gp120 epitope recognized by a broadly neutralizing human monoclonal antibody. J. Virol. 65:6188-6193.
80. Thali, M., C. Furman, D. D. Ho, J. Robinson, S. Tilley, A. Pinter, and J. Sodroski. 1992. Discontinuous, conserved neutralization epitopes overlapping the CD4 binding region of the human immunodeficiency virus type 1 gp120 envelope glycoprotein. J. Virol. 66:5635-5641.
81. Thali, M., C. Furman, E. Helseth, H. Repke, and J. Sodroski. 1992. Lack of correlation between soluble CD4-induced shedding of the human immunodeficiency virus type 1 exterior envelope glycoprotein and subsequent membrane fusion events. J. Virol. 66:5516-5524.
82. Thali, M., J. P. Moore, C. Furman, M. Charles, D. D. Ho, J. Robinson, and J. Sodroski. 1993. Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J. Virol. 67:3978-3988.
83. Tilley, S. A., W. J. Honnen, M. Racho, M. Hilgartner, and A. Pinter. 1991. A human monoclonal antibody against the CD4 binding site of HIV-1 gp120 exhibits potent, broadly neutralizing activity. Res. Virol. 142:247-259.
84. Traunecker, A., W. Luke, and K. Karjalainen. 1988. Soluble CD4 molecules neutralize human immunodeficiency virus type 1. Nature 331:84-86.
85. Trkola, A., T. Dragic, J. Arthos, J. Binley, W. Olson, G. Allaway, C. Cheng-Mayer, J. Robinson, P. Maddon, and J. Moore. 1996. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature 384:184-187.
86. Westervelt, P., H. E. Gendelman, and L. Ratner. 1991. Identification of a determinant within the human immunodeficiency virus type 1 surface envelope glycoprotein critical for productive infection of primary monocytes. Proc. Natl. Acad. Sci. USA 88:3097-3101.
87. Westervelt, P., D. B. Trowbridge, L. G. Epstein, B. M. Blumberg, Y. Li, B. H. Hahn, G. M. Shaw, R. W. Price, and L. Ratner. 1992. Macrophage tropism determinants of human immunodeficiency virus type 1 in vivo. J. Virol. 66:2577-2582.
88. Wiley, D., and J. Skehel. 1987. The structure and function of the hemagglutinin membrane glycoprotein of influenza virus. Annu. Rev. Biochem. 56: 365-394.
89. Wu, L., N. Gerard, R. Wyatt, H. Choe, C. Parolin, N. Ruffing, A. Boresetti, A. Cardoso, E. Desjardins, W. Newman, C. Gerard, and J. Sodroski. 1996. CD4-induced interaction of primary HTV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature 384:179-183.
90. Wyatt, R., N. Sullivan, M. Thali, H. Repke, D. Ho, J. Robinson, M. Posner, and J. Sodroski. 1993. Characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions. J. Virol. 67:4557-4565.
91. Wyatt, R., J. Moore, M. Accola, E. Desjardin, J. Robinson, and J. Sodroski. 1995 Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding. J. Virol. 69:5723-5733.